ARCHIVES

FDA Approives Lilly’s Alimta For 1st-Line Metastatic NSCLC

This article is from The Cancer Letter archive.

Vol. 31 No. 9 | September 26, 2008

Download PDF Visit The Full Archive

Related Articles

Pepper’s Legacy Included NCI, Other Biomedical Research

June 9, 1989

In Brief: VP-16 NDA Approved By FDA Only For Refractory Testicular Cancer; Removed From Group C List

December 2, 1983

NCI Advisory Group, Other Cancer Meetings for Oct., Nov., Future

September 29, 1989

ACS California Division Offers Fellowships For Clinical Research

June 14, 1996

Funding Opportunities: RFAs For Mouse Models Consortium, Urology Research Centers

August 7, 1998

FDA unlikely to pull Iressa from market. Iressa a case study in how not to develop a drug, ODAC member says.

April 1, 2005